Redhill Biopharma Ltd (RDHL)

14.78
NASDAQ : Health Care
Prev Close 14.77
Day Low/High 14.60 / 14.91
52 Wk Low/High 8.10 / 16.54
Avg Volume 33.60K
Exchange NASDAQ
Shares Outstanding 12.71M
Market Cap 187.75M
EPS -1.90
P/E Ratio 77.74
Div & Yield N.A. (N.A)

Latest News

RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea

RedHill Biopharma And IntelGenx Announce RIZAPORT® Commercialization Term Sheet With Pharmatronic Co. For Korea
RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™

RedHill Biopharma Announces Research Collaboration With Stanford University For YELIVA™
RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center

RedHill Biopharma Announces Phase Ib/II Study With YELIVA™ Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center

RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference

RedHill Biopharma To Present At The 9th Annual BioPharm America International Partnering Conference

RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference

RedHill Biopharma To Present At The Rodman & Renshaw 18th Annual Global Investment Conference

RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis

RedHill Biopharma Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis

One Small Pharma Stock Has Big Potential

One Small Pharma Stock Has Big Potential

Redhill has some promising drugs in its pipeline, and is well funded.

RedHill Biopharma Provides 2016 Semi-Annual R&D Update

RedHill Biopharma Provides 2016 Semi-Annual R&D Update

RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis

RedHill Biopharma Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

RedHill Biopharma Reports 2016 Second Quarter Financial Results

RedHill Biopharma Reports 2016 Second Quarter Financial Results

RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection

RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead Of Confirmatory Phase III Study For H. Pylori Infection

RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016

RedHill Biopharma To Host Second Quarter 2016 Financial Results Conference Call On July 26, 2016

RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment

RedHill Biopharma Announces Research Collaboration With NIH For Potential Ebola Treatment

RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories

RedHill Biopharma And IntelGenx Announce Definitive Agreement For Commercialization Of RIZAPORT™ For Migraines With Grupo JUSTE In Spain And Additional Potential Territories

RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection

RedHill Biopharma Announces Publication Demonstrating Potential Efficacy Of RHB-104 For Crohn's Disease Associated With MAP Infection

RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors

RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors

RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors

RedHill Biopharma Announces Positive Final Results With Primary And Secondary Endpoints Met In Phase 1 Study With YELIVA™ In Advanced Solid Tumors

RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D

RedHill Biopharma Announces First Patients Dosed In Phase II Study With BEKINDA™ For IBS-D

RedHill Biopharma To Present At JMP Securities Life Sciences Conference

RedHill Biopharma To Present At JMP Securities Life Sciences Conference

RedHill Biopharma To Present At The 2016 BIO International Convention

RedHill Biopharma To Present At The 2016 BIO International Convention

RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference

RedHill Biopharma To Present At Jefferies 2016 Healthcare Conference

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA™ Phase II Hepatocellular Carcinoma Study

RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit

RedHill Biopharma To Present At BioNetwork East 2016 Partnering Summit

RedHill Biopharma Reports 2016 First Quarter Financial Results

RedHill Biopharma Reports 2016 First Quarter Financial Results

RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases

RedHill Biopharma To Participate In The FBR & Co. Healthcare Series Focused On Infectious Diseases

RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection

RedHill Biopharma Announces Positive FDA Meeting On RHB-105 Path To Approval And Planned Confirmatory Phase III Study For H. Pylori Infection

RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016

RedHill Biopharma To Host First Quarter 2016 Financial Results Conference Call On April 20, 2016

RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome

RedHill Biopharma Initiates Phase II Study Of BEKINDA™ For Irritable Bowel Syndrome

Load More
Quant Rating on 3:59 PM EDT 9/23/2016

D

(Sell)

From Our Partners

RedHill Biopharma: Multiple Shots On Goal And A Low-Risk Pipeline
SeekingAlpha

How To Profit From Selecting The Right 'Tier 4' Biotech Stocks
SeekingAlpha

'Positive momentum' building for RedHill Biopharma, says Roth Capital
The Fly

RedHill Biopharma initiated with a Buy at Nomura
The Fly

RedHill Biopharma data positive, says Roth Capital
The Fly

RedHill Biopharma price target raised to $30 on positive data at Roth Capital
The Fly

RedHill Biopharma initiated with a Buy at H.C. Wainwright
The Fly
Stocks you follow Edit
Authors you follow Edit
My Reading List
save an article here

Trending
25 Highest-Earning Graduate Schools
Twritter, Apple, Nike: Kass' Views
15 Foods to Avoid if You Have High Cholesterol
10 Highest-Paying Jobs in 2016 If All You Care About Is Money
Schisms Between the Stock Market and Stock Prices: Doug Kass